Icon

INVOKANA (nda204042)- (100MG,300MG)

CANAGLIFLOZIN JANSSEN PHARMS
100MG,300MG
Yes No
2031-May-11 2018-Mar-29
None None
None No
INVOKANA is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated:  as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus  to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease  to reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria.
0 7 0
Total Other Developers 7
Drugs with Suitability No
100MG ** ** Up - -
300MG ** ** Up - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.